Recombinant allergenic proteins from ragweed pollen |
| The present invention relates to allergenic proteins or peptides from ragweed, DNAs encoding all or ... |
|
Nucleic acids encoding allergenic proteins from ragweed |
| The present invention relates to allergenic proteins or peptides from ragweed, DNAs encoding all or ... |
|
Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
| OF THE INVENTION As used herein and in the claims, the term "animal" means mammals and avians, ... |
|
Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria |
| What is claimed is: 1. An isolated and purified DNA molecule encoding a hybrid protein, said hybrid ... |
|
Lentiviral packaging constructs |
| OF THE INVENTION The practice of the present invention will employ, unless otherwise indicated, ... |
|
Method for measuring no synthase activity |
| OF THE INVENTION In the context of the present invention the following definitions apply: I... |
|
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
| In one aspect, the present invention pertains to the discovery herein that Wnt polypeptides ("Wnts")... |
|
Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
| The invention relates to a composition for delivery of a virus vector to an animal cell. The ... |
|
Particle delivery techniques |
| OF THE PREFERRED EMBODIMENTS The practice of the present invention will employ, unless otherwise ... |
|
|
Antisense modulation of P38 mitogen activated protein kinase expression
| Details |
Inventors: Monia, Brett P.; Gaarde, William A.; Nero, Pamela S.; McKay, Robert;
Assignee: Isis Pharmaceuticals Inc. (Carlsbad, CA)
Primary Examiner: Elliott; George C.
Assistant Examiner: Epps; Janet L
Attorney, Agent or Firm: Law Offices of Jane Massey Licata
Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided. |
|
DETAILED DESCRIPTION OF THE INVENTION p38 MAPKs play an important role in signal transduction in response to cytokines, growth factors and other cellular stimuli. Specific responses elicited by p38 include inflammatory and apoptotic responses. Modulation of p38 may be useful in the treatment of inflammatory diseases, such as rheumatoid arthritis. The present invention employs antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding a p38 MAPK, ultimately modulating the amount of a p38 MAPK produced. This is accomplished by providing oligonucleotides which specifically hybridize with nucleic acids, preferably mRNA, encoding a p38 MAPK. The antisense compounds may be used to modulate the function of a particular p38 MAPK isoform, e. g. for research purposes to determine the role of a particular isoform in a normal or disease process, or to treat a disease or condition that may be associated with a particular isoform. It may also be desirable to target multiple p38 MAPK isoforms. In each case, antisense compounds can be designed by taking advantage of sequence homology between the various isoforms. If an antisense compound to a particular isoform is desired, then the antisense compound is designed to a unique region in the desired isoform's gene sequence. With such a compound, it is desirable that this compound does not inhibit the expression of other isoforms. Less desirable, but acceptable, are compounds that do not substantially inhibit other isoforms. By "substantially", it is intended that these compounds do not inhibit the expression of other isoforms greater than 25%; more preferred are compounds that do not inhibit other isoforms greater than 10%. If an antisense compound is desired to target multiple p38 isoforms, then regions of significant homology between the isoforms can be used. This relationship between an antisense compound such as an oligonucleotide and its complementary nucleic acid target, to which it hybridizes, is commonly referred to as "antisense"
|
| Related patents |
|
|
Antisense modulation of CD44 expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense modulation of Smad7 expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense modulation of nucleolin expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense modulation of hnRNP A1 expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense inhibition of E2F transcription factor 3 expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense inhibition of rank expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense inhibition of protein kinase C-theta expression
OF THE INVENTION The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid ...
|
|
|
Antisense oligonucleotide modulation of human mdm2 expression
OF THE INVENTION Tumors often result from genetic changes in cellular regulatory genes. Among the most important of these are the tumor suppressor genes, of which p53 ...
|
|
|
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
The term "alkyl" as used herein means straight and branched carbon chains of one to twenty carbons, preferably one to six carbons and more preferably one to three ...
|
|
|
Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements
What is claimed is: 1. An antibacterial compound of formula V-L-W-X; wherein: V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria; L is a ...
|
|
|